Drug Profile
Research programme: AAV-based gene therapies - Q32 Bio
Alternative Names: AAVHSC 15; AAVHSC 17; AAVHSC-16Latest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator Beckman Research Institute
- Developer Q32 Bio
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued CNS disorders; Cystic fibrosis; Duchenne muscular dystrophy; Lysosomal storage diseases; Phenylketonuria
Most Recent Events
- 25 Mar 2024 Q32 Bio has merged with Homology Medicines to form Q32 Bio
- 27 Jul 2023 Research programme: AAV-based gene therapies - Homology Medicines is available for licensing as of 27 Jul 2023. https://www.homologymedicines.com/pipeline/
- 27 Jul 2023 Discontinued - Preclinical for Phenylketonuria in USA (IV)